Positive News Sentiment NASDAQ:LPTX Leap Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.22 +0.02 (+1.67%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$1.19▼$1.2750-Day Range$0.96▼$1.3752-Week Range$0.92▼$4.17Volume335,645 shsAverage Volume615,944 shsMarket Capitalization$107.75 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Leap Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside268.9% Upside$4.50 Price TargetShort InterestBearish15.46% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.40) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.87 out of 5 starsMedical Sector623rd out of 1,433 stocksPharmaceutical Preparations Industry305th out of 683 stocks 3.5 Analyst's Opinion Consensus RatingLeap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Leap Therapeutics has a forecasted upside of 268.9% from its current price of $1.22.Amount of Analyst CoverageLeap Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.46% of the outstanding shares of Leap Therapeutics have been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 17.2, which indicates bearish sentiment.Change versus previous monthShort interest in Leap Therapeutics has recently decreased by 1.09%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPTX. Previous Next 3.3 News and Social Media Coverage News SentimentLeap Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.Search Interest7 people have searched for LPTX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.80% of the stock of Leap Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Leap Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Leap Therapeutics (NASDAQ:LPTX) StockLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Read More LPTX Stock News HeadlinesMay 19, 2022 | finance.yahoo.comWe're Keeping An Eye On Leap Therapeutics' (NASDAQ:LPTX) Cash Burn RateMay 13, 2022 | finance.yahoo.comLeap Therapeutics Reports First Quarter 2022 Financial ResultsApril 9, 2022 | finance.yahoo.comShareholders in Leap Therapeutics (NASDAQ:LPTX) are in the red if they invested five years agoMarch 19, 2022 | finance.yahoo.comLeap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 15, 2022 | benzinga.comLeap Therapeutics's Return On Capital Employed InsightsMarch 11, 2022 | benzinga.comLeap Therapeutics: Q4 Earnings InsightsFebruary 8, 2022 | finance.yahoo.comHow Many Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares Do Institutions Own?January 31, 2022 | seekingalpha.comLeap Therapeutics forms partnership to develop companion diagnostic for cancer patientsJanuary 24, 2022 | finance.yahoo.comLeap Therapeutics to Present at B. Riley Securities Oncology Investor ConferenceJanuary 19, 2022 | marketwatch.comLeap Therapeutics Shares Rise Premarket on Encouraging Study Data >LPTXJanuary 12, 2022 | finance.yahoo.comHedge Funds Are Crazy About LEAP THERAPEUTICS, INC. (LPTX)December 21, 2021 | nasdaq.comCompanies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In GrowthDecember 10, 2021 | finance.yahoo.comLeap Therapeutics (NASDAQ:LPTX) Is In A Good Position To Deliver On Growth PlansNovember 15, 2021 | finance.yahoo.comLeap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 12, 2021 | finance.yahoo.comLeap Therapeutics Reports Third Quarter 2021 Financial ResultsNovember 4, 2021 | finance.yahoo.comEarnings Preview: Leap Therapeutics, Inc. (LPTX) Q3 Earnings Expected to DeclineNovember 4, 2021 | finance.yahoo.comEarnings Preview: Leap Therapeutics, Inc. (LPTX) Q3 Earnings Expected to DeclineOctober 11, 2021 | finance.yahoo.comLeap Therapeutics (NASDAQ:LPTX) shareholders have earned a 63% return over the last yearOctober 5, 2021 | finance.yahoo.com3 Biotech Stocks That Surged in SeptemberOctober 1, 2021 | benzinga.comLooking Into Leap Therapeutics's Return On Capital EmployedSeptember 24, 2021 | finance.yahoo.comLeap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesSeptember 22, 2021 | finance.yahoo.comLeap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded WarrantsSeptember 16, 2021 | benzinga.comWhy Leap Therapeutics Shares Are Trading Higher TodaySeptember 13, 2021 | finance.yahoo.comLeap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 CongressSeptember 7, 2021 | finance.yahoo.comLeap Therapeutics to Participate at Two Upcoming Virtual Investor ConferencesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPTX CUSIPN/A CIK1509745 Webwww.leaptx.com Phone(617) 714-0360FaxN/AEmployees36Year FoundedN/ACompany Calendar Last Earnings5/13/2022Today7/07/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$4.50 High Stock Price Forecast$6.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+268.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,590,000.00 Net Margins-2,705.80% Pretax Margin-3,720.27% Return on Equity-47.38% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio14.29 Quick Ratio14.29 Sales & Book Value Annual Sales$1.50 million Price / Sales71.83 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book1.00Miscellaneous Outstanding Shares88,320,000Free Float77,278,000Market Cap$107.75 million OptionableNot Optionable Beta0.64 Leap Therapeutics Frequently Asked Questions Should I buy or sell Leap Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Leap Therapeutics stock. View analyst ratings for Leap Therapeutics or view top-rated stocks. What is Leap Therapeutics' stock price forecast for 2022? 3 equities research analysts have issued 1 year price objectives for Leap Therapeutics' shares. Their LPTX stock forecasts range from $4.00 to $6.00. On average, they expect Leap Therapeutics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 268.9% from the stock's current price. View analysts' price targets for Leap Therapeutics or view top-rated stocks among Wall Street analysts. How has Leap Therapeutics' stock price performed in 2022? Leap Therapeutics' stock was trading at $3.24 at the beginning of 2022. Since then, LPTX shares have decreased by 62.3% and is now trading at $1.22. View the best growth stocks for 2022 here. When is Leap Therapeutics' next earnings date? Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Leap Therapeutics. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings data on Friday, May, 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Leap Therapeutics had a negative net margin of 2,705.80% and a negative trailing twelve-month return on equity of 47.38%. View Leap Therapeutics' earnings history. Who are Leap Therapeutics' key executives? Leap Therapeutics' management team includes the following people: Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director (Age 53, Pay $1.04M)Mr. Augustine J. Lawlor, Chief Operating Officer (Age 65, Pay $693.83k)Dr. Cynthia A. Sirard, Chief Medical Officer (Age 52, Pay $691.22k)Mr. Mark O'Mahony, Chief Manufacturing Officer (Age 51)Ms. Christine M. Granfield, VP and Head of Regulatory Affairs & Quality (Age 54)Dr. Jason S. Baum Ph.D., VP & Head of Translational MedicineDr. Walter Newman, Sr. Research Fellow (Age 76) Who are some of Leap Therapeutics' key competitors? Some companies that are related to Leap Therapeutics include Edgewise Therapeutics (EWTX), Karyopharm Therapeutics (KPTI), Protagonist Therapeutics (PTGX), Lexicon Pharmaceuticals (LXRX), BioXcel Therapeutics (BTAI), Generation Bio (GBIO), Vera Therapeutics (VERA), Aerovate Therapeutics (AVTE), Phathom Pharmaceuticals (PHAT), ALX Oncology (ALXO), Affimed (AFMD), Entrada Therapeutics (TRDA), Tyra Biosciences (TYRA), Akero Therapeutics (AKRO) and Seres Therapeutics (MCRB). View all of LPTX's competitors. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL). What is Leap Therapeutics' stock symbol? Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX." How do I buy shares of Leap Therapeutics? Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Leap Therapeutics' stock price today? One share of LPTX stock can currently be purchased for approximately $1.22. How much money does Leap Therapeutics make? Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $107.75 million and generates $1.50 million in revenue each year. The company earns $-40,590,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. How many employees does Leap Therapeutics have? Leap Therapeutics employs 36 workers across the globe. How can I contact Leap Therapeutics? Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for Leap Therapeutics is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com. This page (NASDAQ:LPTX) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
